Bernard Pau

Chairman at Phost’in SAS

Health Technology

Profile

Bernard Pau founded Biodol Therapeutics SAS in 2015.
Dr. Pau also currently works at Phost’in SAS, as Chairman & Chief Operating Officer from 2020.

Bernard Pau active positions

Companies	Position	Start
Phost’in SAS Phost’in SAS Pharmaceuticals: MajorHealth Technology Phost’In SAS operates as a biotechnology company, which engages in the discovery and development of N-glycosylation inhibitors. Its potent anti-cancer new chemical entities specifically targeting abnormal pathogenic glycosylation mechanisms. The company was founded by Karine Chorro and Ludovic Clarion in December 2014 and is headquartered in France.	Chairman	16/06/2020

All active positions of Bernard Pau

Former positions of Bernard Pau

Companies	Position	End
Biodol Therapeutics SAS Biodol Therapeutics SAS BiotechnologyHealth Technology Biodol Therapeutics SAS engages in the development of compounds for the treatment of chronic pain. It specializes in parallel small-molecule FLT3 inhibitors. The company was founded by Fabien Granier, Pierre Sokoloff and Bernard Pau in 2015 and is headquartered in Clapiers, France.	Founder	-

See the detail of Bernard Pau's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Bernard Pau's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Phost’in SAS Phost’in SAS Pharmaceuticals: MajorHealth Technology Phost’In SAS operates as a biotechnology company, which engages in the discovery and development of N-glycosylation inhibitors. Its potent anti-cancer new chemical entities specifically targeting abnormal pathogenic glycosylation mechanisms. The company was founded by Karine Chorro and Ludovic Clarion in December 2014 and is headquartered in France.	Health Technology
Biodol Therapeutics SAS Biodol Therapeutics SAS BiotechnologyHealth Technology Biodol Therapeutics SAS engages in the development of compounds for the treatment of chronic pain. It specializes in parallel small-molecule FLT3 inhibitors. The company was founded by Fabien Granier, Pierre Sokoloff and Bernard Pau in 2015 and is headquartered in Clapiers, France.	Health Technology